Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? [electronic resource]
Producer: 20041209Description: 122-4 p. digitalISSN:- 1540-0352
- Aged
- Androgen Antagonists -- adverse effects
- Clinical Trials, Phase III as Topic
- Docetaxel
- Drug Resistance, Neoplasm
- Humans
- Male
- Middle Aged
- Mitoxantrone -- administration & dosage
- Neoadjuvant Therapy
- Neoplasm Staging
- Prognosis
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Randomized Controlled Trials as Topic
- Risk Assessment
- Survival Analysis
- Taxoids -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.